Well, current EV is sub $10M. Despite, the difficult time biotech globally (incl Aus) has had over the last 2-3 years, this is very cheap for a NCE Phase 1 asset addressing some very large clinical indications.
Before the recent issues they had, it was comfortably trading above 20c (peaked around 50c in the lead up), and I believe deserves to at least get back there once Phase 1 initiation is in sight.
GLTA, A.
NSB Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
